Evidence map›Paper›PMID 28472135›Full record

ArticlePloS one2017

Induction of endogenous retroelements as a potential mechanism for mouse-specific drug-induced carcinogenicity.

Timothy M Coskran, Zhijie Jiang, James E Klaunig, Dixie L Mager, Leslie Obert, Andrew Robertson, Nicholas Tsinoremas, Zemin Wang, Mark Gosink

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Timothy M CoskranDrug Safety Research & Development, Pfizer Inc., Groton, Connecticut, United States of America.
Zhijie JiangDepartment of Computer Science, University of Miami, Miami, Florida, United States of America.
James E KlaunigEnvironmental Health, Indiana University, Bloomington, Indiana, United States of America.
Dixie L MagerTerry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada.
Leslie ObertGlaxoSmithKline plc, King of Prussia, Pennsylvania, United States of America.
Andrew RobertsonDrug Safety Research & Development, Pfizer Inc., Groton, Connecticut, United States of America.
Nicholas TsinoremasDepartment of Computer Science, University of Miami, Miami, Florida, United States of America.
Zemin WangEnvironmental Health, Indiana University, Bloomington, Indiana, United States of America.
Mark GosinkDrug Safety Research & Development, Pfizer Inc., Groton, Connecticut, United States of America.ORCID http://orcid.org/0000-0003-3009-3941
Pfizer (United States) · USIndiana University Bloomington · USUniversity of Miami · USBC Cancer Agency · CAGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A number of chemical compounds have been shown to induce liver tumors in mice but not in other species. While several mechanisms for this species-specific tumorigenicity have been proposed, no definitive mechanism has been established. We examined the effects of the nongenotoxic rodent hepatic carcinogen, WY-14,643, in male mice from a high liver tumor susceptible strain (C3H/HeJ), and from a low tumor susceptible strain (C57BL/6). WY-14,643, a PPARα activator induced widespread increases in the expression of some endogenous retroelements, namely members of LTR and LINE elements in both strains. The expression of a number of known retroviral defense genes was also elevated. We also demonstrated that basal immune-mediated viral defense was elevated in C57BL/6 mice (the resistant strain) and that WY-14,643 further activated those immuno-defense processes. We propose that the previously reported >100X activity of retroelements in mice drives mouse-specific tumorigenicity. We also propose that C57BL/6's competent immune to retroviral activation allows it to remove cells before the activation of these elements can result in significant chromosomal insertions and mutation. Finally, we showed that WY-14,643 treatment induced gene signatures of DNA recombination in the sensitive C3H/HeJ strain.

Indexed as

RetroelementsAnimalsCarcinogensMaleMiceMice, Inbred C3HMice, Inbred C57BLPyrimidinesCarcinogenspirinixic acidPyrimidinesRetroelements

Identifiers

PMID28472135
PMCPMC5417610
OpenAlexW2610289494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.